250602-95-0

Upstream product

• 120743-99-9 p-[(tert-butyldimethylsilyl)oxy]benzaldehyde 
• 250602-92-7 N-[4-(tert-butyldimethylsilyloxy)benzyloxy]phtalimide 
• 250602-93-8 O-[[4-[[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]methyl]hydroxylamine 
• 138585-08-7 (4-((tert-butyldimethylsilyl)oxy)phenyl)methanol 
• 123-08-0 4-hydroxy-benzaldehyde 

Downstream Products

• 250602-32-5 ethyl (E)-6-(4-{[2-(2-furyl)-5-methyl-1,3-oxazol-4-yl]methoxy}benzyloxyimino)-6-phenylhexanoate 
• 250602-34-7 ethyl (E)-6-(4-{[5-methyl-2-(2-thienyl)-1,3-oxazol-4-yl]methoxy}benzyloxyimino)-6-phenylhexanoate 

Relevant academic research and scientific papers

Studies on non-thiazolidinedione antidiabetic Agents. 2. Novel oxyiminoalkanoic acid derivatives as potent glucose and lipid lowering agents

We previously reported that (Z)-2-{4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl) methoxy]benzyloxyimino}-2-(4-phenoxyphenyl)acetic acid (3) showed potent glucose and lipid lowering effects in genetically obese and diabetic mice, KKA y. This compound a